OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Contents page	246
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	216
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	194
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	193
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	170
The recent progress of deep-learning-based in silico prediction of drug combination	157
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	139
CIPDB: A biological structure databank for studying cation and π interactions	129
Tubulin targeting agents and their implications in non-cancer disease management	128
General aspects of powder rheology applied to pharmaceutical formulations	122
Models and approaches to comprehend and address glial inflammation following spinal cord injury	118
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	117
Computational modeling approaches and regulatory pathways for drug combinations	113
Gastroretentive drug delivery systems: A holy grail in oral delivery	110
Antibody–drug conjugates: What drives their progress?	107
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	98
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	91
Specificity of pharmacokinetic modeling of nanomedicines	91
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	89
The potential value of 5-androstenediol in countering acute radiation syndrome	87
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	86
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	84
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	84
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	79
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	78

Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	78
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	77
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	77
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	77
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	76
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	74
Contents page 2	73
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	72
Pathogenic TDP-43 in amyotrophic lateral sclerosis	71
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	70
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	69
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	69
Molecular approaches for the treatment and prevention of Friedreich's ataxia	69
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	68
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	65
Organoids in modelling infectious diseases	62
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	62
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	60
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	60
Targeted protein degradation: current molecular targets, localization, and strategies	60
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	58
MRI assessment of cerebral perfusion in clinical trials	57
Steps toward nebulization in-use studies to understand the stability of new biological entities	57
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	57
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	56
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	56
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	55
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	55
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	55
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	55
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	55